[Cardiovascular toxicity of anti-angiogenic therapy].
The use of anti-angiogenic therapies has revolutionized the treatment of cancer. However, some of these drugs are associated with cardiovascular damage. An early detection and personalized management is necessary to screen and treat an increase in blood pressure, proteinuria or symptomatic left ventricular dysfunction. Angiotensin-converting enzyme inhibitors and angiotensin II antagonists are the first line treatment of this cardiotoxicity. The interruption of treatment is recommended if cardiac manifestations are uncontrolled, unless the expected benefit is greater than the risks.